Reviews
Ivonescimab Dual-Axis Cardiotoxicity: Surveillance Framework for Anti-PD-1/VEGF-A Bispecifics
Hullon et alCardio-Oncology

Ivonescimab is a first-in-class tetravalent, fragment crystallizable (Fc)-silenced bispecific antibody that binds programmed cell death protein 1 (PD-1) and vascular endothelial growth factor-A (VEGF-A) with mutually cooperative avidity. As the lead molecule of a rapidly expanding PD-(L)1/VEGF bispecific class, ivonescimab has demonstrated superiority over both pembrolizumab- and tislelizumab-based regimens in randomized phase III trials and is under regulatory review in the United States. However, the authors note that cardio-oncology currently has no framework addressing its concurrent dual-axis cardiovascular liabilities: vascular toxicity from VEGF signaling pathway inhibition and immune-mediated toxicity from PD-1 blockade.
According to the review, the VEGF-A arm appears to reproduce the class toxicity of VEGF signaling pathway inhibitors, presenting with hypertension and proteinuria as on-target endothelial and glomerular effects, alongside downstream consequences such as thromboembolism and left-ventricular strain. In addition, hemorrhage represents a renewed safety concern now that a survival benefit has been shown in squamous non-small cell lung cancer. Meanwhile, the PD-1 blockade axis carries a low-probability, high-lethality myocarditis hazard, together with pericardial disease, vasculitis, and accelerated atherosclerosis.
The authors appraise that cooperative binding chiefly supports tumor-enriched efficacy rather than systemic vascular protection, as circulating VEGF-A is measurably suppressed and proteinuria occurs in roughly one in five patients. Furthermore, Fc silencing is a coherent but weakly supported rationale for reduced immune toxicity, and intermittent VEGF-A suppression remains an untested basis for vascular sparing. Although ivonescimab’s cardiovascular profile appears favorable within the cohorts studied to date, the authors conclude that its dual mechanisms make it unlikely to be free of cardiovascular risk and propose a risk-stratified bedside surveillance framework, a set of falsifiable predictions, and a cardiovascular core outcome set for the PD-(L)1/VEGF bispecific class.
Key Takeaways
- Ivonescimab has demonstrated superiority over both pembrolizumab- and tislelizumab-based regimens in randomized phase III trials and is under regulatory review in the United States.
- Proteinuria occurs in roughly one in five patients treated with ivonescimab, with the VEGF-A axis reproducing class risks of hypertension, thromboembolism, left-ventricular strain, and hemorrhage.
- The PD-1 inhibition arm carries a low-probability, high-lethality myocarditis hazard alongside risks of pericardial disease, vasculitis, and accelerated atherosclerosis.
Read the original sourceCardio-Oncology
